1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Market Access Impact: Psoriasis (EU5) 2018

Market Access Impact: Psoriasis (EU5) 2018

  • February 2018
  • ID: 5385548
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Market barriers affect just over a fifth of psoriasis prescriptions. Is your brand losing out?

In the EU5, market barriers affect just over a fifth of all psoriasis prescriptions, with the top brand way ahead of its two rivals that are in 2nd and 3rd place. Find out how eliminating barriers would shake up the top and middle of the market, and help the last place brand double its share in Market Access Impact: Psoriasis (EU5) [2018].

Based on a survey of 150 dermatologists, the report covers 10 major therapies from Novartis, AbbVie, Celgene, Leo Pharma, Janssen Cilag, Biogen, Pfizer and Eli Lilly. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways
• Barriers affect just over a fifth of all prescriptions: But two barriers in particular affect more prescriptions than the others.
• Market access is not the problem: Barriers related to market access affect far fewer prescriptions than either of the top two barriers. What are they and what can be done about them?
• Three brands gain share: But the most prescribed brand sees a significantly larger net gain than any other brand.
• One brand loses big: One of the least-prescribed brands loses far more market share than any competitor, and suffers disproportionately from three of the seven barriers.
• Eliminating barriers would close the gaps, but not the rankings: By removing certain barriers, certain brands could improve market share and get closer to rivals. What do you need to do for your brand, and what difference would it make?
• Two brands have a perception problem: Just over 10% of surveyed doctors didn’t even know these two brands exist.

Insight into 10 Major Psoriasis Drugs
• Benepali (etanercept; Biogen)
• Cosentyx (secukinumab; Novartis)
• Enbrel (etanercept; Pfizer)
• Erelzi (etanercept; Sandoz)
• Humira (adalimumab; AbbVie)
• Kyntheum (brodalumab; Leo Pharma)
• Otezla (apremilast; Celgene)
• Stelara (ustekinumab; Janssen Cilag)
• Taltz (ixekizumab; Eli Lilly)
• Tremfya (guselkumab; Janssen Cilag)

Exploring Market Access Barriers

Market Access Impact: Psoriasis (EU5) explores key issues affecting Psoriasis drug manufacturers. You’ll learn:

How barriers affect market access:
• What brands do doctors prescribe the most?
• How many prescriptions do barriers affect?
• Which barriers have the biggest impact?

How barriers affect your brand:
• How many doctors prescribe your brand? How many don’t, but would consider it?
• Why don’t doctors prescribe your brand? What do they prescribe instead?
• Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 dermatologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents:
• Have been practicing for 2+ years
• Prescribed at least one of the listed products
• Seen at least 5 patients in total in the last month

We conducted the survey between February 6-15, 2018.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Amyloidosis - Pipeline Review, H1 2020

Amyloidosis - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Amyloidosis - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H1 2020, provides an overview of the Amyloidosis (Metabolic Disorders) ...

RAC Alpha Serine/Threonine Protein Kinase - Pipeline Review, H1 2020

RAC Alpha Serine/Threonine Protein Kinase - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

RAC Alpha Serine/Threonine Protein Kinase - Pipeline Review, H1 2020SummaryAccording to the recently published report ’RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H1 2020’; RAC Alpha ...

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2019

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on